- Home
- ALT vs TMQ Comparison
ALT vs TMQ Comparison
Compare ALT & TMQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | TMQ |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.8M | 579.8M |
| IPO Year | 2005 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ALT | TMQ |
|---|---|---|
| Price | $2.97 | $3.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 1.1M |
| Earning Date | 05-08-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.56 | $2.00 |
| 52 Week High | $6.44 | $11.29 |
Technical Indicators
Market Signals| Indicator | ALT | TMQ |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 41.53 |
| Support Level | $2.80 | $3.14 |
| Resistance Level | $3.09 | $3.28 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 8.99 | 24.04 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.